Against this background, it is relevant that in the KEEP study elevated systolic blood pressure accounted for the majority of patients with inadequate control. Male gender, non-Hispanic black race, and BMI of 30 kg/m2 or more were inversely related to blood pressure control. What is the blood pressure target for CKD patients? According to the

different BTK inhibitor guidelines published by the major kidney societies, systolic blood pressure should be lowered to values <130 or 125 mmHg if greater than 1 g/day of proteinuria is present. One has to be aware, however, that as a predictor of adverse CKD or cardiovascular events, office blood pressure may be inferior compared to ambulatory blood pressure measurement [11]. This issue is particularly relevant in CKD because of the tendency for nighttime blood pressure to be elevated (little or no nocturnal dip in blood pressure) and the fact that central (aortic) blood pressure tends to be higher Angiogenesis inhibitor than peripheral (brachial) blood pressure [11, 12]. In patients with diabetes, guidelines all recommend that lower blood pressure targets may provide further benefit, but prospective trials have thus far failed to confirm this epidemiological

observation. The role of diabetic nephropathy As indicated above, diabetes and hypertension are the most common causes of CKD. There are currently over 240 million people with diabetes worldwide. This figure is projected to rise to 380 million by 2025, largely due to population growth, aging, urbanization, unhealthy eating habits, increased body fat, and a sedentary lifestyle. By 2025, the number of people with diabetes is expected to more than double in Southeast Asia, the Eastern Mediterranean and Middle East, and Africa. It is projected to rise by nearly 20% in Europe, 50% in North America, 85% in South and Central America, and 75% in the Western Pacific region. The top five countries with the highest prevalence of diabetes in order include India, China, the

US, Russia, and Japan. Worldwide, more than 50% of people with diabetes are unaware of their condition and are not treated. The same behaviors that increase obesity are shared with those predisposed to diabetes, i.e., family history, presence of hypertension, aging, excess body IKK inhibitor weight, lack of exercise, and unhealthy dietary habits. It is important Carnitine palmitoyltransferase II to identify these risks early to reduce the development of diabetes and CKD, since CKD greatly amplifies the risk of cardiovascular events in the diabetic patient. The remaining challenge Under-diagnosis and under-treatment of CKD are worldwide problems: not only is CKD awareness low worldwide, but the relative lack of CKD risk factor awareness by physicians, i.e., hypertension and diabetes, is even more disturbing. Moreover, even awareness of these risk factors does not ensure adequate treatment; this could relate either to the behavior of the patient, the provider, or both.